uniQure Grants Chiesi Select Commercial Rights For The EU’s First Approved Gene Therapy Glybera And Hemo B Gene Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
uniQure has licensed commercial rights covering Europe and select emerging markets to Italy’s Chiesi for first-to-market gene therapy Glybera and a developmental hemophilia B product. The Dutch biopharma is writing the book on pricing and commercialization, regulatory approval, and market access strategy for gene therapy.
You may also be interested in...
Financings Of The Fortnight: IPOs Dominate Early 2014 With 13 Debuts In As Many Days
Insider participation continues to play an important role in getting a majority of biotech IPOs off the ground; and it’s not clear if or when that trend will change. Plus, news on recent financings by Dicerna, uniQure, Lumos Pharma and NightstaRx.
Deals Of The Week Looks At Pricing Conundrums
New therapeutic modalities can bring unexpected challenges in pricing, as uniQure and electroCore learn. Also, deal news from Celgene/OncoMed, Forest/Merck, Theraclone/PharmAthene, The Medicines Company/Rempex and Roche/Molecular Partners.
Chiesi Buys Denmark’s Zymenex For Phase III Enzyme Replacement Therapy
The purchase of Zymenex by Italy’s Chiesi has allowed VC firm Sunstone Capital to reap a second return on its investment in the Danish developer of enzyme replacement therapies.